Common Regulatory Mechanisms Mediated by Cuproptosis Genes in Inflammatory Bowel Disease and Major Depressive...

Area of Science:

• Investigates the intersection of neurogastroenterology and cellular pathology.
• Explores the role of copper metabolism in complex diseases.
• Utilizes multi-omics and computational approaches for disease mechanism discovery.

Background:

• Inflammatory bowel disease (IBD) patients exhibit a higher prevalence of major depressive disorder (MDD).
• The underlying molecular links and the role of cuproptosis-related genes (CRGs) in IBD and MDD remain underexplored.
• Cuproptosis, a form of cell death due to copper overload, is a novel area of investigation in these conditions.

Purpose of the Study:

• To elucidate the molecular mechanisms of CRGs in IBD and MDD.
• To identify shared biomarkers and therapeutic targets for both diseases.
• To explore novel therapeutic strategies through CRG modulation.

Main Methods:

• Identification of differentially expressed CRGs (DE-CRGs) in disease versus normal samples.
• Correlation analysis of CRGs with each other and with immune cell infiltration.
• Application of four machine learning algorithms to pinpoint key CRGs.
• Drug sensitivity analysis, molecular docking, and molecular dynamics simulations for drug prediction.

Main Results:

• Identified common DE-CRGs including DLD, DLAT, DLST, PDHB, and DBT.
• Identified key CRGs associated with both IBD and MDD: DLD, LIAS, SLC31A1, SCO2, and CDKN2A.
• DLD was confirmed as a shared biomarker for IBD and MDD.
• 37 potential therapeutic drugs were identified; barasertib and NTP-TAE684 targeting DLAT showed promise.

Conclusions:

• Significant progress in understanding the shared regulatory mechanisms of CRGs in brain-gut axis diseases.
• Identification of DLD as a potential pan-biomarker for IBD and MDD.
• Prediction of novel therapeutic agents, barasertib and NTP-TAE684, for IBD and MDD treatment.